REPORT ID 1577

EMEA (Europe, Middle East and Africa) Polycystic Ovary Syndrome (PCOS) Drugs Market Report 2017

Publish Date
06-Dec-17
Pages
108
Format
Electronic (PDF)

In this report, the EMEA Polycystic Ovary Syndrome (PCOS) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Polycystic Ovary Syndrome (PCOS) Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Polycystic Ovary Syndrome (PCOS) Drugs market competition by top manufacturers/players, with Polycystic Ovary Syndrome (PCOS) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Sanofi
    Novartis AG
    Teva Pharmaceutical Industries Limited
    Addex Therapeutics Ltd.
    BIOCAD
    Merck KGaA
    AstraZeneca plc.
    Bristol Myers Squibb Co.
    Ferring Pharmaceuticals, Inc.
    Crinetics Pharmaceuticals, Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Oral Contraceptives
    Antiandrogens
    Insulin-sensitizing Agent
    Antidepressant
    Anti-obesity

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Polycystic Ovary Syndrome (PCOS) Drugs Market Report 2017
1 Polycystic Ovary Syndrome (PCOS) Drugs Overview
    1.1 Product Overview and Scope of Polycystic Ovary Syndrome (PCOS) Drugs
    1.2 Classification of Polycystic Ovary Syndrome (PCOS) Drugs
        1.2.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Oral Contraceptives
        1.2.4 Antiandrogens
        1.2.5 Insulin-sensitizing Agent
        1.2.6 Antidepressant
        1.2.7 Anti-obesity
    1.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market by Application/End Users
        1.3.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Clinic
    1.4 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market by Region
        1.4.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Polycystic Ovary Syndrome (PCOS) Drugs (2012-2022)
        1.5.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs (Volume) by Application
    2.4 EMEA Polycystic Ovary Syndrome (PCOS) Drugs (Volume and Value) by Region
        2.4.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales Price by Region (2012-2017)

3 Europe Polycystic Ovary Syndrome (PCOS) Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales and Value (2012-2017)
        3.1.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Type
    3.3 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Application
    3.4 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)

4 Middle East Polycystic Ovary Syndrome (PCOS) Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Type
    4.3 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Application
    4.4 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)

5 Africa Polycystic Ovary Syndrome (PCOS) Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Value (2012-2017)
        5.1.1 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Type
    5.3 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Market Share by Application
    5.4 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Polycystic Ovary Syndrome (PCOS) Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate (2012-2017)

6 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Sanofi
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Sanofi Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Novartis AG
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Novartis AG Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Teva Pharmaceutical Industries Limited
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Teva Pharmaceutical Industries Limited Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Addex Therapeutics Ltd.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Addex Therapeutics Ltd. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 BIOCAD
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 BIOCAD Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Merck KGaA
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Merck KGaA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 AstraZeneca plc.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 AstraZeneca plc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Bristol Myers Squibb Co.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Bristol Myers Squibb Co. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Ferring Pharmaceuticals, Inc.
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Ferring Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Crinetics Pharmaceuticals, Inc.
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Polycystic Ovary Syndrome (PCOS) Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Crinetics Pharmaceuticals, Inc. Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Polycystic Ovary Syndrome (PCOS) Drugs Manufacturing Cost Analysis
    7.1 Polycystic Ovary Syndrome (PCOS) Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Polycystic Ovary Syndrome (PCOS) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Polycystic Ovary Syndrome (PCOS) Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Polycystic Ovary Syndrome (PCOS) Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Market Forecast (2017-2022)
    11.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Polycystic Ovary Syndrome (PCOS) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Polycystic Ovary Syndrome (PCOS) Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer